These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 8423505)
1. Exposure of hospital pharmacists and nurses to antineoplastic agents. McDevitt JJ; Lees PS; McDiarmid MA J Occup Med; 1993 Jan; 35(1):57-60. PubMed ID: 8423505 [TBL] [Abstract][Full Text] [Related]
2. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Acampora A; Castiglia L; Miraglia N; Pieri M; Soave C; Liotti F; Sannolo N Ann Occup Hyg; 2005 Oct; 49(7):611-8. PubMed ID: 15964876 [TBL] [Abstract][Full Text] [Related]
3. Exposure of hospital workers to airborne antineoplastic agents. deWerk Neal A; Wadden RA; Chiou WL Am J Hosp Pharm; 1983 Apr; 40(4):597-601. PubMed ID: 6846365 [TBL] [Abstract][Full Text] [Related]
4. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Pethran A; Schierl R; Hauff K; Grimm CH; Boos KS; Nowak D Int Arch Occup Environ Health; 2003 Feb; 76(1):5-10. PubMed ID: 12592576 [TBL] [Abstract][Full Text] [Related]
5. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696 [TBL] [Abstract][Full Text] [Related]
6. [Determination of airborne and surface contamination with cyclophosphamide at the Masaryk Memorial Cancer Institute, Brno, Czech Republic]. Gorná L; Odráska P; Dolezalová L; Piler P; Oravec M; Bláha L Ceska Slov Farm; 2011 Feb; 60(1):25-31. PubMed ID: 21650015 [TBL] [Abstract][Full Text] [Related]
7. OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Yodaiken RE; Bennett D Am J Hosp Pharm; 1986 May; 43(5):1193-204. PubMed ID: 3717176 [TBL] [Abstract][Full Text] [Related]
8. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Fransman W; Vermeulen R; Kromhout H Ann Occup Hyg; 2004 Apr; 48(3):237-44. PubMed ID: 15059800 [TBL] [Abstract][Full Text] [Related]
9. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Fransman W; Peelen S; Hilhorst S; Roeleveld N; Heederik D; Kromhout H Ann Occup Hyg; 2007 Apr; 51(3):231-9. PubMed ID: 17337460 [TBL] [Abstract][Full Text] [Related]
10. Sampling for airborne fluorouracil in a hospital drug preparation area. McDiarmid MA; Egan T; Furio M; Bonacci M; Watts SR Am J Hosp Pharm; 1986 Aug; 43(8):1942-5. PubMed ID: 3752134 [TBL] [Abstract][Full Text] [Related]
11. Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. Sugiura S; Asano M; Kinoshita K; Tanimura M; Nabeshima T J Oncol Pharm Pract; 2011 Mar; 17(1):14-9. PubMed ID: 20179165 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. Hedmer M; Jönsson BA; Nygren O J Environ Monit; 2004 Dec; 6(12):979-84. PubMed ID: 15568047 [TBL] [Abstract][Full Text] [Related]
13. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
14. [Risk assessment concerning hospital personnel participating in the preparation and administration of antineoplastic drugs]. Minoia C; Turci R; Sottani C; Schiavi A; Perbellini L; Angeleri S; Frigerio F; Draicchio F; Apostoli P G Ital Med Lav Ergon; 1999; 21(2):93-107. PubMed ID: 10771723 [TBL] [Abstract][Full Text] [Related]
15. Utilization of the solid sorbent media in monitoring of airborne cyclophosphamide concentrations and the implications for occupational hygiene. Odraska P; Dolezalova L; Piler P; Oravec M; Blaha L J Environ Monit; 2011 May; 13(5):1480-7. PubMed ID: 21468422 [TBL] [Abstract][Full Text] [Related]
16. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760 [TBL] [Abstract][Full Text] [Related]
17. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C; Turci R; Sottani C; Schiavi A; Perbellini L; Angeleri S; Draicchio F; Apostoli P Rapid Commun Mass Spectrom; 1998; 12(20):1485-93. PubMed ID: 9796535 [TBL] [Abstract][Full Text] [Related]
18. Handling anticancer drugs: from hazard identification to risk management? Sorsa M; Hämeilä M; Järviluoma E Ann N Y Acad Sci; 2006 Sep; 1076():628-34. PubMed ID: 17119240 [TBL] [Abstract][Full Text] [Related]
19. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. Hedmer M; Wohlfart G J Environ Monit; 2012 Jul; 14(7):1968-75. PubMed ID: 22692549 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of surface contamination in a hospital hematology--oncology pharmacy. Touzin K; Bussières JF; Langlois E; Lefebvre M J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]